HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration - Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation Geneva, Switzerland, March 27, 2023 – HpVac SA, a company developing novel preventive and...

HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer - Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...